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Q Fever in Young 
Children, Ghana
To the Editor: Recently, ex-
perts identiﬁ  ed Q fever, caused by the 
small, gram-negative bacterium Coxi-
ella burnetii, as an important underdi-
agnosed childhood disease (1). Stud-
ies on Q fever in children <5 years of 
age are scarce, especially with respect 
to sub-Saharan Africa. The only avail-
able study from Niger reports a sero-
prevalence of 9.6% (2). Throughout 
Africa, prevalence of Q fever in adults 
shows considerable variability and is 
highest in countries with prominent 
stockbreeding (3).
Clinical manifestations of Q fe-
ver in children are similar to those 
of malaria (1,4). In malaria-endemic 
areas, most fevers are attributed to 
Plasmodium falciparum infection and 
presumptively treated with expensive 
combination therapies (5). In this con-
text, other neglected fever-causing 
pathogens need to be given appropri-
ate consideration.
We studied the prevalence of Q 
fever antibodies in 219 randomly se-
lected children living in 9 rural villages 
of the Ashanti region, Ghana. Plasma 
was obtained by venous puncture from 
2-year-old children after they had par-
ticipated in a malaria control study 
and had been clinically monitored for 
21 months. Clinical, parasitologic, so-
cioeconomic, and Global Positioning 
System information was recorded as 
described elsewhere (6,7). In addition, 
158 healthy adult volunteers from the 
same area were included. Plasma was 
stored at –20°C until microimmuno-
ﬂ   uorescence assays (IFA) (Coxiella 
burnetii I+II, Vircell SL Microbiolo-
gists, Granada, Spain) were performed 
according to manufacturer’s instruc-
tions. To identify all children with 
Q fever titers, we regarded the fol-
lowing as positive ﬂ  uorescence reac-
tions to plasma dilutions: >1:64 for 
phase II immunoglobulin (Ig) G and 
>1:24 for phase II IgM with sensitiv-
ity (speciﬁ  city) of 97.2% (100%) and 
100% (56.3%), respectively. IgM test-
ing was only performed on IgG-posi-
tive children. Positive and negative 
controls were run on each IFA slide. 
Relative risks (RR) for characteristics 
of children were calculated by χ2 test; 
p<0.05 was considered signiﬁ  cant. In-
formed consent was obtained from all 
participants or their parents. The study 
protocol was approved by the com-
mittee on human research and publi-
cation, Kwame Nkrumah University 
of Science and Technology, Kumasi, 
Ghana.
Positive C. burnetii phase II IgG 
responses were observed in 37 (16.9%) 
of 219 children and 14 (8.9%) of 158 
adults (Figure, panels A and B). In 
comparison to adults, more children 
had IgG titers >64 (Figure, panels C 
and D). On the day of the serosurvey 
71 (32.4%) of 219 children had fever 
(measured body temperature >38°C or 
reported fever within the previous 48 
hours). Test outcome did not appear to 
be inﬂ  uenced by P. falciparum infec-
tion, since 4 of 37 IgG-positive children 
(23 of 182 IgG-negative children) had 
clinical malaria, 11/37 (62/182) had 
asymptomatic parasitemia, and 6/37 
(38/182) had fever without parasitemia, 
and there were no signiﬁ  cant differences 
between groups. The frequency of prior 
malaria episodes also did not inﬂ  uence 
antibody response. Three aparasitemic 
children had positive phase II IgM ti-
ters (24, 96, and 1,536; phase II IgG 64, 
64, and 4,096, respectively). The child 
with the high IgM and IgG titers was 
clinically ill with nonsevere C. burnetii 
pneumonia. This child was among 10 
(27%) of 37 phase II IgG-positive chil-
dren with detectable anti–C. burnetii 
phase I antibodies. Of all sociodemo-
graphic characteristics under consid-
eration, only maternal illiteracy was 
associated with positive phase II IgG 
testing (RR 2.1, 95% conﬁ  dence inter-
val 1.0–4.2, p<0.05).
A considerable proportion of 
Ghanaian children had anti–C. bur-
netii antibodies, which indicates that 
Q fever might be a common event in 
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this age group. Antibodies were more 
frequently detected in children than in 
adults. In adults, Q fever IgG antibod-
ies reach a maximum 4–8 weeks after 
onset of symptoms and gradually de-
crease over months to ﬁ  nally fall be-
low the detection limit (8).
A long period since infection is 
less likely in young children, which 
could result in higher seropositiv-
ity. Children, especially those of il-
literate mothers, could also be more 
frequently exposed to the pathogen. 
Consumption of unpasteurized dairy 
products can result in infection or se-
roconversion without clinical disease 
(9). However, because consumption 
of raw milk in the Ashanti region is 
regarded as being uncommon by lo-
cal health authorities, we consider 
dairy products an unlikely source of 
the disease. Although participants 
were intensively exposed to P. falci-
parum, which causes polyclonal B-
cell stimulation, malaria episodes and 
parasitemia with and without symp-
toms at time of the serosurvey did not 
inﬂ   uence testing (10). This ﬁ  nding 
is important because commercially 
available test kits have only been 
evaluated in Europeans not exposed 
to parasites. We cannot completely 
rule out the possibility that other in-
fectious agents, which are either only 
prevalent or more prevalent in Afri-
can populations, could have resulted 
in false-positive results. Nevertheless, 
the test method we used and existing 
data on cross-reactions weaken this 
hypothesis (8).
We conclude that children in rural 
sub-Saharan Africa become exposed 
to  C. burnetii early in life and that 
Q fever, which is clinically indistin-
guishable from malaria, may develop 
in an unknown proportion of them. 
The incidence of Q fever in relation to 
malaria, the route of infection, and ap-
propriate serologic cutoffs for sub-Sa-
haran Africa must be deﬁ  ned further. 
Currently, a prospective diagnostic 
study is investigating neglected infec-
tions, including human Q fever, as a 
cause of illness in Ghanaian children.
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Figure. Seroprevalence of immunoglobulin (Ig) G antibodies against Coxiella burnetii 
phase II tested by microimmunoﬂ  uorescence assays (IFA). A) Results of serologic tests of 
children, a cutoff titer of >64 for C. burnetii phase II IgG was applied; B) results of serologic 
tests of healthy adults (cutoff >64); C) distribution of C. burnetii phase II IgG titers in all 
positive children; D) distribution of IgG titers in all positive healthy adults.
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Early Diagnosis of 
Disseminated 
Mycobacterium 
genavense Infection 
To the Editor: Nontuberculous 
mycobacteria are environmental or-
ganisms that cause life-threatening 
diseases, particularly in immunocom-
promised hosts. They are increasingly 
recognized for causing problems in 
the management of solid-organ trans-
plant recipients, due to improved di-
agnostic methods as well as increasing 
numbers and life expectancy of these 
patients (1). The slow-growing Myco-
bacterium genavense is a ubiquitous 
nontuberculous mycobacterium; it is 
reportedly isolated from tap water, 
pets, and the gastrointestinal tract of 
healthy humans (1,2). It was ﬁ  rst rec-
ognized as a human pathogen in a pa-
tient with AIDS but has not yet been 
found in heart transplant recipients 
(3). We report early diagnosis of dis-
seminated M. genavense infection in a 
heart transplant recipient.
A 37-year-old man was hospital-
ized in September 2001 for abdomi-
nal pain, sweats, and weight loss; he 
had received a heart transplant 3 years 
earlier. Immunosuppressive treatment, 
which began immediately after trans-
plantation, consisted of tacrolimus (5 
mg) and mycophenolate mofetil (2 g) 
daily; concurrent steroid therapy was 
tapered off over the next 6 months. 
A computed tomographic (CT) scan 
showed numerous large lymph nodes 
in his abdomen (Figure). Endoscopic 
examinations showed diffuse inﬂ  am-
mation of the mucosa of the duodenum, 
ileum, and colon. Multiple biopsy 
samples were submitted for histologic 
analysis, culture, and molecular bio-
logical analysis. Immediate 16S rRNA 
gene ampliﬁ  cation that used universal 
primers (4) and sequencing of sam-
ples taken directly from the biopsy 
material led to the identiﬁ  cation of M. 
genavense. A 475-bp fragment was 
sequenced, and 99% homology with 
the gene of type strain ATCC 51234 
(GenBank accession no. X60070) was 
found. PCR results were positive for 2 
of the 4 samples tested. The molecular 
identiﬁ  cation was compatible with the 
subsequent histologic ﬁ  nding of pro-
found macrophage inﬁ  ltration  with-
out granuloma and the presence of 
Ziehl-Neelsen–positive bacilli. Five 
weeks later, the molecular diagno-
sis was conﬁ  rmed by blood cultures 
and cultures of the intestinal mucosa 
samples (Inno-LiPA Mycobacteria 
test, version 2, Innogenetics, Courta-
boeuf, France). The direct molecular 
diagnosis of M. genavense enabled 
immediate treatment of the patient 
with the combination of moxiﬂ  oxa-
cin, ethambutol, clarithromycin, and 
amikacin; mycophenolate mofetil was 
discontinued. Clofazimine was added 
to the treatment regimen 3 months 
later, when a control CT scan showed 
that some of the enlarged mesenteric 
lymph nodes had increased further. 
After 5 months, the clinical signs re-
solved, and after 9 months, the lymph 
nodes were substantially smaller. CT 
scan results were within normal lim-
its after 12 months of treatment; only 
ethambutol and clarithromycin were 
continued for an additional 6 months. 
There was no sign of M. genavense 
infection relapse 3 years after the di-
agnosis had been made. 
Nontuberculous mycobacteria in 
persons who have received heart or 
other solid-organ transplants remain 
a rare cause of late infectious com-
plications and occur ≈3.5 years after 
transplantation (1,4). In the subgroup 
of heart transplant recipients, skin dis-
ease is the most common clinical man-
ifestation, followed by pulmonary and 
disseminated disease; M. kansasii, M. 
avium complex, and M. haemophilum 
infections are most frequently encoun-
tered (1,5).
M. genavense causes up to 12.8% 
of all nontuberculous mycobacteria 
infections in AIDS patients; these in-
fections are clinically similar to those 
caused by the M. avium complex (1,6). 
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Figure. Initial computed tomographic scan of the abdomen, performed after intravenous 
injection of contrast dye, showing numerous enlarged para-aortic lymph nodes (arrow).